BioProtocol (BIO) fluctuates 42.5% in 24 hours: EliLilly acquisition news and whale purchases drive rebound
Bitget Pulse2026/04/30 07:46Volatility Overview
In the past 24 hours, the price of BIO rebounded from a low of $0.03204 to a high of $0.04565, with the current quote at $0.0455, marking an overall amplitude of 42.5%. The 24-hour trading volume surged significantly to approximately $179 million, a sharp increase from usual levels, indicating heightened capital activity.
Brief Analysis of Market Movements
- Eli Lilly's acquisition of Crossbridge Bio (a VitaDAO derivative project) triggered BIO to become one of the day's hot coins, driving a price rebound and pushing it to the top of the trending list.
- A whale opened a $602k long position on Hyperliquid, combined with the upcoming Peptide TGE (Token Generation Event) and a staking priority mechanism, stimulating short-term buying interest.
- Technically, the price broke above the 8-hour descending wedge upper boundary, accompanied by increased trading volume, forming a series of higher highs.
Market Views and Outlook
The mainstream sentiment within the community is bullish, with several traders considering it “this week’s free long opportunity,” predicting further movement toward $0.0435-$0.056, but emphasize not to chase highs and to wait for pullbacks to enter, while warning against potential FOMO traps in the evening. Analysts point out the rebound potential at $0.045, but note that attention should be paid to the sustainability of the DeSci sector's valuation.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic showcases research achievements ahead of IPO: Claude "autonomously discovers" CRISPR-like systems, gene editing sector faces "AI replacement anxiety"
On Wednesday, U.S. gene editing company stocks declined after Anthropic announced that its AI model Claude had "independently discovered" a new type of enzyme system similar to the gene editing tool CRISPR.
Fed raises rate to 4%, Bitcoin climbs above $86,000 as Lee predicts rally
Australian Dollar tumbles amid soaring US yields, ahead of jobs data
Oil prices are still dominating gold pricing
